Breakpoints19 Feb 2021

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
Watt M, et al. Infection. 2016;44(5):599-606.
Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
Splinter et al. Ann Pharmacother. 2018;52:113-119.
Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(134)

#126 – What’s the Microbiome Gut to Do with It

Dr. Julie Ann Justo is joined by experts Drs. Krista Gens and Javier A. Villafuerte Gálvez as they dive deep into the gut microbiome and explore the latest therapeutic frontier for C. difficile infect...

14 Nov 20251h 8min

#125 – The Scariest and Baddest: Burkholderia, Achromobacter, and Elizabethkingia

Drs. Maria Mojica, Robert Bonomo, and Ryan Shields join Dr. Erin McCreary (@erinmccreary) for a Halloween special reviewing the scariest resistance mechanisms and baddest bugs – Burkholderia spp., Ach...

31 Okt 20251h 32min

#124 – Dosing Consult: Cefepime

Drs. Erin Barreto (@erin_barreto) and Jeffrey Lipman join Dr. Whitney Buckel for a conversation on ideal dosing of cefepime. Hear from the experts on the differences between package insert and “high-d...

10 Okt 20251h 16min

#123 – Rol del Farmacéutico en los PROA en América Latina

En nuestro primer episodio publicado tanto en inglés como en español, la Dra. Laila Woc-Colburn y el QF. Nicolás Ignacio Valdebenito Farías se unen al Dr. José Pablo Díaz Madriz para hablar sobre el p...

26 Sep 202555min

#122 – The Role of The Pharmacist in Antimicrobial Stewardship in Latin America

In our first episode released in both English and Spanish, Drs. Laila Woc-Colburn and Nicholás Ignacio Valdebenito Farías join Dr. José Pablo Díaz Madriz to discuss the role of the pharmacist in antim...

26 Sep 202550min

#121 – Finding BALANCE in Antibiotic Durations: The BALANCE Trial

In this second-ever collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite the two principal investigators and visionaries who spear...

19 Sep 20251h 9min

#120 – What’s Pneu in Community-Acquired Pneumonia

Drs. Whitney Hartlage (@whithartlage11) and Sam Windham join Dr. Ryan Moenster to discuss updates in the diagnosis and management of community-acquire pneumonia. Hear from our guests on the role of ra...

22 Aug 20251h 6min

#119 – Dosing Consult: Fluconazole

Drs. David Andes and Isabel Spriet join Dr. Jeannette Bouchard to discuss all of the top questions our audience had on fluconazole dosing. Who needs a load? How much fluconazole is too much fluconazol...

25 Jul 202551min